At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top China based CFO’ operating in the Pharmaceutical space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Chief Financial Officer of Zai Lab
Billy Cho is our chief financial officer since March 2018. Prior to joining Zai Lab, Billy Cho was the Managing Director and Head of Asia Healthcare Investment Banking at Citigroup. Based in Hong Kong since 2011, Billy Cho was responsible for healthcare client coverage at Citigroup across the Asia Pacific region and led many important biopharma transactions in China including ZaiLab’s US IPO. Prior to this, he was based in New York in healthcare M&A investment banking and also spent time in corporate development for a pharmaceutical services company. Billy Cho started his career at Ernst & Young performing financial audits of US-based healthcare companies. Billy Cho earned his M.B.A. from the Wharton School of the University of Pennsylvania and M.A. in Accounting from University of Virginia.
Follow Billy Cho:
About Zai Lab: Zai Lab brings transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world.
Chief Financial Officer of Shanghai Henlius Biotech
The company Chief Financial Officer, Dr. Zidong Zhang graduated from Fudan University for BS in chemistry, then obtained Ph.D. degree from Boston University in Biochemistry and MBA from Duke University the Fuqua School of Business. Dr. Zhang had worked as Equity Analyst for UBS in New York, covering US large Cap Pharmaceuticals and Specialty Pharmaceutical sector. He had a key focus in therapeutic areas as Oncology(especially for Immuno Oncology), autoimmune diseases, and other areas as Women’s health and CNS. He also developed a specialty and in-depth knowledge in generics market entry pathway and bio-similar entry/competition. Before UBS, healso worked for Bayer in the US as an internal consultant. He had multiple projects across US, Europe, and China, including strategic planning and market forecasts for US and China, merger and acquisition, organizational structure design and implementation, etc.
Follow Zidong Zhang:
About Novotech, Shanghai Henlius Biotech: Shanghai Henlius Biotech is joint venture company that provides clinical-stage biopharmaceutical services.
Chief Financial Officer of CStone Pharmaceuticals
Follow Richard Yeh:
About CStone Pharmaceuticals: CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
CFO of 3D Medicines
Follow Simon Xu:
About 3D Medicines: 3D Medicines mission is to improve people’s health through cancer personalized diagnostics and treatment.
Chief Financial Officer of China Biologic Products
Yang has been our Chief Financial Officer since August 7, 2012, interim Chief Financial Officer since June 1, 2012 and our Vice President of Finance and Compliance and Treasurer since March 30, 2012. He is in charge of financial management, internal controls, legal and compliance matters as well as the implementation of corporate governance rules and policies. Mr. Yang has six years of financial management experience in corporations and 11 years audit experience in accounting firms. Mr. Yang has extensive experience in dealing with the PRC tax regulations, PRC GAAP, IFRS and internal control matters. He was an audit senior manager at KPMG, where he provided audit services for initial public offerings, right issues and merger and acquisition transactions. He also worked on the annual reports of various public companies listed in Hong Kong and mainland China. His audit clients ranged from state-owned enterprises and Chinese listed companies to multinational companies, including Angang Steel, Shenhua Energy, BOE Technology and BHP Billiton. Mr. Yang is a certified public accountant in China.
Follow Ming Yang:
About China Biologic Products: China Biologic Products is a company focused on the plasma-based biopharmaceutical industry.
CFO of Laviana Pharma
Follow Ling Lu:
About Laviana Pharma: Laviana Pharmatech specializes in providing process and manufacture outsourcing services for the pharmaceutical industry.
Vice President and Chief Financial Officer of China Resources Sanjiu Pharmaceutical
Lin Guolong has been Chief Financial Officer and Vice President in China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since August 2011. He used to be Deputy Finance Manager, Finance Manager, Seniro Manager, Assistant General Manager and Deputy General Manager in a group.
Follow Lin Guolong:
About China Resources Sanjiu Pharmaceutical: China Resources Sanjiu Pharmaceutical is a large state-owned pharmaceutical listed company.
CFO of FORESEE PHARMACEUTICALS, INC.
Max Chan is a reputable corporate executive with more than 20 years of experience, including 10 years as CFO of public companies listed on NASDAQ and TPEx. Prior to joining JHL Biotech in Oct. 2015, Max Chan was CFO of TaiGen Biopharmaceuticals (TPEx: 4157.TWO) from 2010 to 2015, CFO of Himax Technologies (NASDAQ: HIMX) from 2004 to 2010, treasury manager of Intel Capital, the strategic investment division of Intel Corporation (NASDAQ: INTC) from 2000 to 2004, senior associate of Credit Suisse First Boston (NYSE: CS) in 2000, and manager at the Overseas Direct Investment Department of China Development Industry Bank (TAIEX: 2883.TW) from 1992 to 2000. Max Chan holds a B.S. degree in civil engineering and an M.B.A. degree in finance from National Taiwan University, and an M.S. degree in business administration from the University of Illinois at Urbana-Champaign.
Follow Max Chan:
About FORESEE PHARMACEUTICALS, INC.: FORESEE PHARMACEUTICALS, INC. is a pharmaceutical business located in Newark, Delaware, United States.
Chief Financial Officer of Hebron Technology
Mr. Fu is our Chief Financial Officer. Mr. Fu started his employment with Hebron Technology in January 2014. From 2009 through 2013, Mr. Fu was the Director of Asia Pacific, International Alliance Associates, with chief financial officer responsibilities. Mr. Fu earned his degree in Accounting from Nanyang Technological University, Singapore. He has over 18 years of investment and financing experience in Asia, along with restructuring work experience. Mr. Fu is proficient in managing various aspects of the investment market across various industries. He has extensive experience in both the private equity market and the stock market.
Follow Steven Fu:
About Hebron Technology: Hebron, a developer, manufacturer and installer of valves and pipe fittings for use in the pharmaceutical, biological, food and beverages.
CFO of Fuwei Films
Follow Xiuyong Zhang:
About Fuwei Films: Fuwei Films (Shandong) Co., Ltd. is a Chinese professional biaxially oriented polyester film (BOPET) manufacturer.